Form 4: Beta Bionics CCO Executes Planned Stock Sale

Chief Commercial Officer Mark Hopman sold 275 shares of Beta Bionics common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., sold 275 shares of common stock.
• The transaction occurred on June 4, 2026, at a price of $12.31 per share.
• Following the sale, the reporting person retains beneficial ownership of 130,612 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a negligible portion of the executive's total holdings.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, indicating the sale was scheduled in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate practice for liquidity and diversification, and typically does not signal a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading liability.

Stakeholder Impact

• Minimal impact on shareholders as the transaction size is small and pre-planned.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, Rule 10b5-1, Chief Commercial Officer